GlaxoSmithKline

GlaxoSmithKline   (Big pharma)
File:GSK logo svg.svg
Formation	December 2000
Headquarters	980 Great West Rd, Brentford, London, UK
Leaders	• GlaxoSmithKline/CEO • GlaxoSmithKline/Director
Interest of	John Buse, Human Genome Sciences, Tachi Yamada
Member of	Alliance for Biosecurity, European Policy Centre, Friends of Europe
Founder of	Galvani Bioelectronics
Subpage	•GlaxoSmithKline/Board •GlaxoSmithKline/CEO •GlaxoSmithKline/Director

 

An event carried out

Event	Location	Description
Foster child drug trials	New York US	National Institutes of Health and Big Pharma force fed experimental pharmaceuticals to infants, toddlers, children and teenagers in New York and elsewhere in the United States.

 

Related Quotation

Page	Quote	Author	Date
Warren Buffett	“In the pharmaceutical world of economic durable competitive advantages, having a patent on a best-selling drug is about as good as it gets. The next best thing is having a monopoly on selling a country’s national health program the vaccines it needs for its childhood inoculation programs. Both of these businesses are hugely profitable and GSK (GlaxoSmithKline) excels in both these categories. The vaccine business is particularly attractive because an individual shot (or jab) costs GSK approximately $1.50 to manufacture and it sells to national vaccine programs for approximately $9 a shot. That gives GSK a net profit of approximately $7.50 a shot. This markup gives GSK a very healthy profit margin that improves with each and every new disease that the company develops a vaccine for. Consider this: GSK's profits rose 10% with the 2009 Swine Flu outbreak—a disease for which the company had a state-of-the-art vaccine ready to inoculate the masses. In addition to its patents and the durable competitive advantage GSK has with the vaccines, it also established the relationships with the world's governments, and it has the financial capital to create, manufacture, and sell vaccines on a world scale. If you were in charge of the health of a nation's 30 million-plus children, who would you buy your vaccines from? Every year? Year after year? You’d pick the biggest and the best. There are only four pharmaceutical giants that control most of the vaccine production in the world and GSK is one of them. There is another component to the vaccine equation that also spells BIG MONEY: Every year, women all over the world give birth to approximately 133 million new babies, 4.3 million babies in the U.S. alone. With the United States Centers for Disease Control (CDC) recommending that children aged birth through six receive 34 individual vaccine shots/jabs, that means the market for those 34 vaccine shots/jabs increases every year by 4.3 million in just the U.S. alone. This in turn means that the vaccine manufacturers selling in the U.S. have the potential to earn a profit of $1.09 billion every year (4.3 million x 34 x $7.50 = $1.09 billion). Consider the number of yearly vaccines worldwide and the numbers are staggering—approximately $34 billion a year (133 million x 34 x $7.50 = $33.9 billion). After ten years, in the U.S. alone, vaccine manufacturers will see more than $10 billion in net profit. On a world scale, the number jumps to a potential $340 billion in profits. And wait, it gets even better. With the invention of each new vaccine comes a patent that is good for twenty years and guarantees that no one else can make the vaccine. In other words, the company has a monopoly. Even when the patents expire, other companies rarely step into the market because the major manufacturers have a permanent relationship with the government health departments of the world. This enables manufacturers to continue making the same vaccines year after year while maintaining their large profit margins even after their patents have expired. And last but not least, vaccine manufacturers in the US are completely immune from lawsuits. Back in the 1980s several bad batches of vaccines injured so many children that the resulting successful lawsuits threatened to bankrupt the manufacturers, so the manufacturers lobbied a bill through Congress making them a protected class.”	Warren Buffett Mary Buffett	2011

 

Employees on Wikispooks

Employee	Job	Appointed	End	Description
Paul Girolami	CEO	April 1980	1986	Company still called Glaxo
Paul Girolami	Chairman	10 December 1985	November 1994	Company still called Glaxo
Jan Leschly	Chief Executive and Director of SmithKline Beecham	1994	May 2000	Attended 3 Bilderberg meetings, in 1998, 1999 and 2002.
Richard Sykes (Big Pharma)	Chairman	1997	2001
Patrick Vallance	President of R & D	2012	2018
Patrick Vallance	Head of drug discovery	2006

 

Related Document

Title	Type	Publication date	Author(s)	Description
Document:Why Barnard Castle	blog post	24 May 2020	Craig Murray	On 12 April 2020 Dominic Cummings was seen in Castle Barnard during lockdown. Two days later, GSK of Barnard Castle signed an agreement to develop and manufacture a vaccine with Sanofi of France.

Many thanks to our Patrons who cover ~2/3 of our hosting bill. Please join them if you can.

References

This is a page stub. Please add to it.